For example, an Anti-CD16 × CD33 bispecific antibody for the treatment of myelodysplastic syndrome (MDS) has been reported to eradicate CD33+ MDS cells and targeted CD33+ myeloid-derived suppressor cells resulting in reduced immunosuppression in the TME and enhanced antitumor efficacy.21 Here, CD33 is linked to myelodysplastic syndrome.